Cantor Fitzgerald analyst Sarah James maintains $HCA Healthcare (HCA.US)$ with a buy rating, and adjusts the target price from $315 to $405.
According to TipRanks data, the analyst has a success rate of 60.1% and a total average return of 8.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The firm projected some disruptions due to hurricanes but did not foresee the company's 2025 EBITDA and EPS projections falling below street expectations, which is a reversal from a previous period of consistent outperformance. Despite being intrigued by the recent 9% stock decline, the firm suggests that the shares may experience a phase of consolidation going forward.
HCA Healthcare's third-quarter performance managed to withstand the negative impacts of hurricanes, a trend that's anticipated to persist into the fourth quarter and possibly lead to a fiscal year 2024 guidance that aligns with the lower end of expectations. Despite the ongoing challenges posed by these natural disasters, the company's management is projecting earnings growth for 2025 to meet or exceed its long-term objectives, supported by an admissions growth prediction of 3%-4%, which is considered above the usual trend.
Investor expectations were high leading into the third quarter, yet HCA Healthcare's underlying performance remained robust, evidenced by same-store revenues climbing 7.1% despite a strong third-quarter comparison from the previous year at 7.9%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析師Sarah James維持$HCA醫療 (HCA.US)$買入評級，並將目標價從315美元上調至405美元。
根據TipRanks數據顯示，該分析師近一年總勝率為60.1%，總平均回報率為8.4%。
此外，綜合報道，$HCA醫療 (HCA.US)$近期主要分析師觀點如下：
該公司預測由於颶風可能導致一些中斷，但並未預見到公司2025年的EBITDA和每股收益低於市場預期，這與之前持續表現優異的時期形成反轉。儘管對最近股價下跌9%感到好奇，但該公司表示股票可能會經歷一段整固階段。
hca醫療的第三季度業績成功抵禦了颶風的負面影響，這一趨勢預計將持續到第四季度，並可能導致財年2024年的指引與預期下限保持一致。儘管面臨自然災害帶來的持續挑戰，公司管理層預計2025年的盈利增長將達到或超過其長期目標，支撐因入院增長預測爲3%-4%，這被認爲高於通常趨勢。
投資者對第三季度的預期很高，然而，hca醫療的基本業績表現依然強勁，同店銷售收入增長了7.1%，儘管與前一年強勁的第三季度比較爲7.9%。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
